It is shown that increased sampling and AlphaFold3 generally improve performance relative to default sampling and AlphaFold2, however predictive accuracy and improvement levels varied considerably among interface classes, with antibody-peptide complexes representing a challenge despite their small antigen size.
Abstract
Determining the structural basis of antigen recognition by antibodies and T cell receptors (TCRs) provides critical insights into effective immune targeting and can inform design of biotherapeutics and vaccines. Accurate computational modeling of antibodies and TCRs in complex with their targets poses a major challenge for predictive methods, including AlphaFold, which is generally accurate for modeling protein complexes but has shown limited success for immune recognition. In this study we assessed the performance of AlphaFold2, AlphaFold3, increased sampling protocols, and related deep learning methods for modeling antibody-protein, antibody-peptide, and TCR-peptide-major histocompatibility complex (pMHC) recognition. We show that increased sampling and AlphaFold3 generally improve performance relative to default sampling and AlphaFold2, however predictive accuracy and improvement levels varied considerably among interface classes, with antibody-peptide complexes representing a challenge despite their small antigen size. Comparing per-case success across methods showed some complementarity, indicating opportunities for increased success through model pooling approaches, for instance increasing antibody-peptide near-native success from 41% to 59%. Analysis of AlphaFold confidence scores and modeling of a noncanonical complex provided further insights into predictive performance. These results highlight considerations for predictive antibody and TCR complex modeling efforts, while revealing key distinctions among protocols, scoring, and immune complex classes.
This review compiles the data resources related to polyreactive antibodies and places a particular emphasis on computational models for predicting antibody polyreactivity, which includes empirical models based on physicochemical properties, traditional machine learning models, deep learning networks, and protein langua...
Haoxian Tang, Zixuan Zhang, Wenzhi Li et al.· Computational Biomedicine· 0 citations
The ImmunoFoundation Model (IFM), a multimodal deep learning system that integrates not only peptide sequences, 3D molecular structures, and biochemical properties but also TCR-MHC-peptide to achieve superior immunogenicity prediction and enable peptide optimization for therapeutic applications is developed.
Smita Krishnaswamy, J. Rocha, Hiren Madhu et al.· Journal of Immunology· 0 citations
An ensemble approach (enFoldX) that leverages structure prediction models such as AlphaFold3 to build sensitive binding predictors and outperforms the current co-folding methods which rely on predictions from the single top ranked structure.
O. Lyudovyk, Jonathan A. Levine, M. Pathil et al.· Clinical Cancer Research· 0 citations
AAMFM, an Antigen-specific Antibody Multimodal Foundation Model that learns unified representations of antibody sequences and structures conditioned on antigen context, achieves state-of-the-art performance in functional antibody design, revealing its potential for antigen-specific antibody engineering.
Xiaoliang Shi, Zichen Wang, Runze Ma et al.· arXiv.org· 0 citations
CLDN18.2 is a promising tumor-specific antigen; however, the development of therapeutic antibodies against it is challenged by the need for simultaneous optimization of affinity and developability. To address this, we present cdrGPT, a deep learning framework based on GPT-2 for de novo generation of complementarity-det...
Tao Qu, Lingyan Yuan, Wei-Ran Cui et al.· PLoS Computational Biology· 0 citations
An ensemble approach (enFoldX) that leverages structure prediction models such as AlphaFold3 to build sensitive binding predictors and outperforms the current co-folding methods which rely on predictions from the single top ranked structure.
O. Lyudovyk, Jonathan A. Levine, M. Pathil et al.· Clinical Cancer Research· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.